Sudarshan Pharma [SUDARSHAN] vs Foseco India Limited [FOSECOIND] Detailed Stock Comparison
Sudarshan Pharma
BSE
Loading...
Foseco India Limited
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma wins in 6 metrics, Foseco India Limited wins in 12 metrics, with 0 ties. Foseco India Limited appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma | Foseco India Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.86 | 43.67 | Sudarshan Pharma |
| Price-to-Book Ratio | 4.76 | 9.67 | Sudarshan Pharma |
| Debt-to-Equity Ratio | 129.85 | 0.42 | Foseco India Limited |
| PEG Ratio | N/A | 2.66 | N/A |
| EV/EBITDA | 16.49 | 32.47 | Sudarshan Pharma |
| Profit Margin (TTM) | 3.83% | 14.05% | Foseco India Limited |
| Operating Margin (TTM) | 6.99% | 15.72% | Foseco India Limited |
| EBITDA Margin (TTM) | 6.99% | 15.72% | Foseco India Limited |
| Return on Equity | 12.13% | 24.30% | Foseco India Limited |
| Return on Assets (TTM) | 3.96% | 11.97% | Foseco India Limited |
| Free Cash Flow (TTM) | $304.76M | $267.09M | Sudarshan Pharma |
| Dividend Yield | N/A | 0.54% | N/A |
| 1-Year Return | -93.27% | 19.83% | Foseco India Limited |
| Price-to-Sales Ratio (TTM) | 1.13 | 6.18 | Sudarshan Pharma |
| Enterprise Value | $7.94B | $32.86B | Foseco India Limited |
| EV/Revenue Ratio | 1.44 | 5.64 | Sudarshan Pharma |
| Gross Profit Margin (TTM) | 11.05% | 44.71% | Foseco India Limited |
| Revenue per Share (TTM) | $23 | $913 | Foseco India Limited |
| Earnings per Share (Diluted) | $0.87 | $128.17 | Foseco India Limited |
| Beta (Stock Volatility) | 0.68 | 0.06 | Foseco India Limited |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sudarshan Pharma vs Foseco India Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | 4.99% | 4.88% | -15.13% | -6.93% | -11.29% | -38.71% |
| Foseco India Limited | -0.95% | 2.07% | -10.82% | 12.04% | 68.68% | 35.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | -93.27% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
| Foseco India Limited | 19.83% | 193.06% | 375.18% | 312.81% | 1,116.61% | 1,398.14% |
News Based Sentiment: Sudarshan Pharma vs Foseco India Limited
Sudarshan Pharma
News based Sentiment: NEGATIVE
Sudarshan Pharma faces significant headwinds, including a substantial year-to-date stock decline, negative analyst ratings predicting a 48% decline, and concerning valuation metrics. While the upcoming IPO presents a potential opportunity, the overall narrative is one of caution and risk, making this a pivotal moment for the company.
Foseco India Limited
News based Sentiment: POSITIVE
Foseco India is demonstrating strong year-to-date returns and preparing for a key earnings release on November 6, 2025. While there's some short-term stock fluctuation, the long-term performance and upcoming results suggest a generally positive outlook for investors.
Performance & Financial Health Analysis: Sudarshan Pharma vs Foseco India Limited
| Metric | SUDARSHAN | FOSECOIND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.56B | ₹35.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 53,200 | 6,270 |
| 90 Day Avg. Volume | 77,333 | 22,115 |
| Last Close | ₹28.63 | ₹5,585.50 |
| 52 Week Range | ₹24.69 - ₹53.50 | ₹3,205.00 - ₹6,846.00 |
| % from 52W High | -46.49% | -18.41% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹6,846.00 (Sep 08, 2025) |
| % from All-Time High | -93.68% | -18.41% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | 0.26% |
| Quarterly Earnings Growth | N/A | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.14% |
| Operating Margin (TTM) | 0.07% | 0.16% |
| Return on Equity (TTM) | 0.12% | 0.24% |
| Debt to Equity (MRQ) | 129.85 | 0.42 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.46 | ₹578.81 |
| Cash per Share (MRQ) | ₹0.09 | ₹453.34 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹629.85M |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹457.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.54% |
| Last 12-Month Dividend | N/A | ₹25.00 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma vs Foseco India Limited
| Metric | SUDARSHAN | FOSECOIND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.86 | 43.67 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | 2.66 |
| Price to Sales (TTM) | 1.13 | 6.18 |
| Price to Book (MRQ) | 4.76 | 9.67 |
| Market Capitalization | ||
| Market Capitalization | ₹6.56B | ₹35.95B |
| Enterprise Value | ₹7.94B | ₹32.86B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 5.64 |
| Enterprise to EBITDA | 16.49 | 32.47 |
| Risk & Other Metrics | ||
| Beta | 0.68 | 0.06 |
| Book Value per Share (MRQ) | ₹5.46 | ₹578.81 |
Financial Statements Comparison: Sudarshan Pharma vs Foseco India Limited
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUDARSHAN | FOSECOIND |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹1.57B |
| Cost of Goods Sold | ₹1.29B | ₹869.49M |
| Gross Profit | ₹160.46M | ₹703.03M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹101.60M | ₹247.17M |
| EBITDA | ₹122.50M | ₹315.80M |
| Pre-Tax Income | ₹54.09M | ₹291.10M |
| Income Tax | ₹14.51M | ₹75.76M |
| Net Income (Profit) | ₹39.59M | ₹215.34M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUDARSHAN | FOSECOIND |
|---|---|---|
| Cash & Equivalents | ₹5.51M | ₹906.63M |
| Total Current Assets | ₹3.35B | ₹4.30B |
| Total Current Liabilities | ₹2.60B | ₹1.38B |
| Long-Term Debt | ₹104.60M | ₹13.22M |
| Total Shareholders Equity | ₹1.31B | ₹3.43B |
| Retained Earnings | N/A | ₹2.80B |
| Property, Plant & Equipment | ₹200.50M | ₹11.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUDARSHAN | FOSECOIND |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | FOSECOIND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 53,200 | 6,270 |
| Average Daily Volume (90 Day) | 77,333 | 22,115 |
| Shares Outstanding | 240.66M | 6.39M |
| Float Shares | 71.19M | 829,478 |
| % Held by Insiders | 0.76% | 0.86% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma vs Foseco India Limited
| Metric | SUDARSHAN | FOSECOIND |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹25.00 |
| Last 12-Month Dividend Yield | N/A | 0.54% |
| 3-Year Avg Annual Dividend | N/A | ₹21.67 |
| 3-Year Avg Dividend Yield | N/A | 0.60% |
| 3-Year Total Dividends | N/A | ₹65.00 |
| Ex-Dividend Date | N/A | May 14, 2025 |